McKesson (NYSE:MCK) Updates FY 2027 Earnings Guidance
by Amy Steele · The Cerbat GemMcKesson (NYSE:MCK – Get Free Report) issued an update on its FY 2027 earnings guidance on Thursday morning. The company provided earnings per share guidance of 43.800-44.600 for the period, compared to the consensus earnings per share estimate of 44.130. The company issued revenue guidance of -.
McKesson Price Performance
Shares of McKesson stock traded up $9.76 during trading hours on Thursday, reaching $753.43. The company’s stock had a trading volume of 1,941,689 shares, compared to its average volume of 802,130. The firm has a 50 day moving average price of $887.83 and a 200-day moving average price of $860.18. McKesson has a one year low of $637.00 and a one year high of $999.00. The stock has a market cap of $92.29 billion, a P/E ratio of 21.67, a P/E/G ratio of 1.16 and a beta of 0.35.
McKesson (NYSE:MCK – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported $11.69 earnings per share for the quarter, topping analysts’ consensus estimates of $11.56 by $0.13. McKesson had a net margin of 1.09% and a negative return on equity of 338.97%. The company had revenue of $96.30 billion for the quarter, compared to analyst estimates of $101.35 billion. McKesson has set its FY 2027 guidance at 43.800-44.600 EPS. As a group, sell-side analysts forecast that McKesson will post 39.02 EPS for the current fiscal year.
McKesson Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 1st. Investors of record on Monday, June 1st will be given a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Monday, June 1st. McKesson’s dividend payout ratio is 9.43%.
Analyst Upgrades and Downgrades
A number of research firms recently weighed in on MCK. Leerink Partners reissued an “outperform” rating and issued a $1,085.00 price objective on shares of McKesson in a research report on Thursday, March 5th. Mizuho increased their price objective on shares of McKesson from $880.00 to $885.00 and gave the stock a “neutral” rating in a research report on Thursday, February 5th. TD Cowen raised their target price on shares of McKesson from $1,000.00 to $1,012.00 and gave the stock a “buy” rating in a research report on Thursday, February 5th. Bank of America reduced their target price on shares of McKesson from $1,040.00 to $1,000.00 and set a “buy” rating on the stock in a research report on Monday, April 6th. Finally, Barclays raised their target price on shares of McKesson from $960.00 to $1,050.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 18th. Fourteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $972.27.
Check Out Our Latest Stock Report on MCK
Insider Activity at McKesson
In other news, CAO Napoleon B. Rutledge, Jr. sold 328 shares of the stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $955.00, for a total transaction of $313,240.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Leann B. Smith sold 190 shares of the stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $945.00, for a total transaction of $179,550.00. Following the transaction, the executive vice president owned 2,989 shares in the company, valued at approximately $2,824,605. This represents a 5.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 3,592 shares of company stock valued at $3,518,555. 0.08% of the stock is owned by insiders.
Hedge Funds Weigh In On McKesson
A number of hedge funds and other institutional investors have recently modified their holdings of the business. SurgoCap Partners LP raised its holdings in shares of McKesson by 68.7% in the third quarter. SurgoCap Partners LP now owns 452,261 shares of the company’s stock worth $349,390,000 after buying an additional 184,106 shares during the last quarter. Wellington Management Group LLP boosted its position in McKesson by 32.9% in the third quarter. Wellington Management Group LLP now owns 618,984 shares of the company’s stock valued at $478,190,000 after buying an additional 153,182 shares during the last quarter. Invesco Ltd. boosted its position in McKesson by 9.5% in the fourth quarter. Invesco Ltd. now owns 1,052,739 shares of the company’s stock valued at $863,551,000 after buying an additional 90,982 shares during the last quarter. AQR Capital Management LLC raised its holdings in shares of McKesson by 10.8% during the fourth quarter. AQR Capital Management LLC now owns 918,785 shares of the company’s stock worth $753,671,000 after purchasing an additional 89,747 shares during the last quarter. Finally, Canada Pension Plan Investment Board raised its holdings in shares of McKesson by 443.0% during the second quarter. Canada Pension Plan Investment Board now owns 105,613 shares of the company’s stock worth $77,391,000 after purchasing an additional 86,162 shares during the last quarter. 85.07% of the stock is currently owned by institutional investors.
McKesson Company Profile
McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.
The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.